Overview

A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7058584 Following 7 Days of Instillation of Eye Drops in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

Status:
Completed

Trial end date:
2017-12-21

Target enrollment:

Participant gender:

Summary

This is a Phase I, multi-center, randomized, adaptive, investigator/patient-masked, placebo-controlled, parallel multiple-ascending dose study (Part A) with an extension including up to two selected doses from Part A and latanoprost 0.005% as active comparator (Part B).

Phase:

Phase 1

Details

Lead Sponsor:

Hoffmann-La Roche

Treatments:

Latanoprost
Ophthalmic Solutions